Cardiovascular Business August 15, 2022
Michael Walter

Boston Scientific has announced its acquisition of Obsidio, a South Carolina-based medical device company that developed a new hydrogel material for the embolization of blood vessels. Specific financial details of the deal have not been shared with the public.

Obsidio’s Gel Embolic Material technology, or GEL for short, is delivered through a catheter and immediately conforms to the patient’s vasculature, forming a barrier. It was cleared by the U.S. Food and Drug Administration in July.

Biomedical engineer Ehsan Jabbarzadeh, PhD, a professor with the University of South Carolina, and interventional radiologist Rahmi Oklu, MD, PhD, a professor with the Mayo Clinic campus in Phoenix, founded Obsidio in 2019. In July 2021, the company secured a research grant from the National...

Today's Sponsors

Institute for Healthcare Improvement
Crossover Health

Today's Sponsors


Today's Sponsor


Topics: Medical Devices, Mergers & Acquisitions / JV, Trends
Intelerad acquires mammo software maker PenRad Technologies
Take Command Acquires Technology from Savvy to Expand Benefits Platform
How leaders at Salesforce, Zoom, and Best Buy are using technology to change health care
Atrium, Advocate Aurora merger to accelerate digital health innovation
Intermountain, SCL Health merger to bolster innovation, telehealth